NCT03361436View on ClinicalTrials.gov

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

February 14, 2023

Study Completion Date

April 14, 2033

Conditions
LiposarcomaMalignant Abdominal NeoplasmMalignant Retroperitoneal NeoplasmMalignant Scrotal NeoplasmMalignant Solid NeoplasmMalignant Spermatic Cord Neoplasm
Interventions
DRUG

Eribulin Mesylate

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER